A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico

被引:18
作者
Diaz-Zabala, Hector J. [1 ]
Ortiz, Ana P. [2 ]
Garland, Lisa [3 ]
Jones, Kristine [3 ]
Perez, Cynthia M. [4 ]
Mora, Edna [5 ,6 ]
Arroyo, Nelly [1 ]
Oleksyk, Taras K. [7 ,8 ]
Echenique, Miguel [9 ]
Matta, Jaime L. [1 ]
Dean, Michael [10 ]
Dutil, Julie [1 ]
机构
[1] Ponce Hlth Sci Univ, Ponce Res Inst, Canc Biol Div, Ponce, PR 00716 USA
[2] Univ Puerto Rico, Comprehens Canc Ctr, Canc Control & Populat Sci Program, San Juan, PR 00936 USA
[3] Leidos Biomed Res Inc, Canc Genom Res Lab, Frederick, MD 21702 USA
[4] Univ Puerto Rico, Grad Sch Publ Hlth, Dept Biostat & Epidemiol, San Juan, PR 00936 USA
[5] Univ Puerto Rico, Sch Med, Dept Surg, San Juan, PR 00936 USA
[6] Univ Puerto Rico, Comprehens Canc Ctr, San Juan, PR 00936 USA
[7] Oakland Univ, Biol Dept, Rochester, MI 48309 USA
[8] Univ Puerto Rico, Dept Biol, Mayaguez, PR 00681 USA
[9] Auxilio Mutuo Hosp, Canc Ctr, San Juan, PR 00936 USA
[10] NCI, Div Canc Epidemiol & Genet, Lab Translat Genom, Gaithersburg, MD 20877 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
breast cancer genetics; BRCA1/BRCA2; founder effect; Hispanic and Latino populations; SURGICAL ADJUVANT BREAST; RISK-ASSESSMENT; HIGH PROPORTION; BOWEL PROJECT; IDENTIFICATION; PREVALENCE; ANCESTRY; CARRIERS; SUBSTITUTIONS; PERFORMANCE;
D O I
10.3390/cancers10110419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the most common cause of cancer diagnosis in women and is responsible for considerable mortality among the women of Puerto Rico. However, there are few studies in Puerto Rico on the genetic factors influencing risk. To determine the contribution of pathogenic mutations in BRCA1 and BRCA2, we sequenced these genes in 302 cases from two separate medical centers, who were not selected for age of onset or family history. We identified nine cases that are carriers of pathogenic germline mutation. This represents 2.9% of unselected cases and 5.6% of women meeting National Comprehensive Cancer Network (NCCN) criteria for BRCA testing. All of the identified pathogenic mutations were in the BRCA2 gene and the most common mutation is the p.Glu1308Ter (E1308X) mutation in BRCA2 found in eight out of nine cases, representing 89% of the pathogenic carriers. The E1308X mutation has been identified in breast and ovarian cancer families in Spain, and analysis of flanking DNA polymorphisms shows that all E1308X carriers occur on the same haplotype. This is consistent with BRCA2 E1308X being a founder mutation for the Puerto Rican population. These results will contribute to better inform genetic screening and counseling of breast and ovarian cancer cases in Puerto Rico and Puerto Rican populations in mainland United States.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
    Phillips, Kelly-Anne
    Milne, Roger L.
    Rookus, Matti A.
    Daly, Mary B.
    Antoniou, Antonis C.
    Peock, Susan
    Frost, Debra
    Easton, Douglas F.
    Ellis, Steve
    Friedlander, Michael L.
    Buys, Saundra S.
    Andrieu, Nadine
    Nogues, Catherine
    Stoppa-Lyonnet, Dominique
    Bonadona, Valerie
    Pujol, Pascal
    McLachlan, Sue Anne
    John, Esther M.
    Hooning, Maartje J.
    Seynaeve, Caroline
    Tollenaar, Rob A. E. M.
    Goldgar, David E.
    Terry, Mary Beth
    Caldes, Trinidad
    Weideman, Prue C.
    Andrulis, Irene L.
    Singer, Christian F.
    Birch, Kate
    Simard, Jacques
    Southey, Melissa C.
    Olsson, Hakan L.
    Jakubowska, Anna
    Olah, Edith
    Gerdes, Anne-Marie
    Foretova, Lenka
    Hopper, John L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3091 - 3099
  • [32] Genetic Variants in the 3'UTR of BRCA1 and BRCA2 Genes and Their Putative Effects on the microRNA Mechanism in Hereditary Breast and Ovarian Cancer
    Marisela Sanchez-Chaparro, Maria
    Garza-Veloz, Idalia
    Alejandro Zayas-Villanueva, Omar
    Martinez-Fierro, Margarita L.
    Delgado-Enciso, Ivan
    Alejandra Gomez-Govea, Mayra
    Elia Martinez-de-Villarreal, Laura
    Resendez-Perez, Diana
    Pablo Rodriguez-Sanchez, Iram
    DIAGNOSTICS, 2020, 10 (05)
  • [33] Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history
    Kang, Peter Choon Eng
    Phuah, Sze Yee
    Sivanandan, Kavitta
    Kang, In Nee
    Thirthagiri, Eswary
    Liu, Jian Jun
    Hassan, Norhashimah
    Yoon, Sook-Yee
    Thong, Meow Keong
    Hui, Miao
    Hartman, Mikael
    Yip, Cheng Har
    Taib, Nur Aishah Mohd
    Teo, Soo Hwang
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 144 (03) : 635 - 642
  • [34] Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
    Xia, Yue Yin
    Gronwald, Jacek
    Karlan, Beth
    Lubinski, Jan
    McCuaig, Jeanna M.
    Brooks, Jennifer
    Moller, Pal
    Eisen, Andrea
    Sun, Sophie
    Senter, Leigha
    Bordeleau, Louise
    Neuhausen, Susan L.
    Singer, Christian F.
    Tung, Nadine
    Foulkes, William D.
    Sun, Ping
    Narod, Steven A.
    Kotsopoulos, Joanne
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 514 - 521
  • [35] Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer
    Nicolussi, Arianna
    Belardinilli, Francesca
    Mandavian, Yasaman
    Colicchia, Valeria
    D'Inzeo, Sonia
    Petrone, Marialaura
    Zani, Massimo
    Ferraro, Sergio
    Valentini, Virginia
    Ottini, Laura
    Giannini, Giuseppe
    Capalbo, Carlo
    Coppa, Anna
    PEERJ, 2019, 7
  • [36] Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?
    Emiroglu, Selman
    Ozkurt, Enver
    Cabioglu, Neslihan
    Igci, Abdullah
    Saip, Pinar
    Yazici, Hulya
    Ozmen, Tolga
    Ozmen, Vahit
    Muslumanoglu, Mahmut
    Tukenmez, Mustafa
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 163 - 173
  • [37] No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families
    Imbert-Bouteille, Marion
    Corsini, Carole
    Picot, Marie-Christine
    Mizrahy, Lucas
    Akouete, Sandrine
    Huguet, Helena
    Thomas, Frederic
    Genevieve, David
    Taourel, Patrice
    Ychou, Marc
    Galibert, Virginie
    Rideau, Chloe
    Baudry, Karen
    Kubiak, Tatiana Kogut
    Coupier, Isabelle
    Hobeika, Remy
    Macary, Yvette
    Toledano, Alain
    Solassol, Jerome
    Maalouf, Antoine
    Daures, Jean-Pierre
    Pujol, Pascal
    GENES, 2021, 12 (07)
  • [38] Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies
    Park, Junli
    Huang, Dan
    Chang, Yoon Jung
    Lim, Myong Cheol
    Myung, Seung-Kwon
    CARCINOGENESIS, 2022, 43 (03) : 231 - 242
  • [39] Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation
    Corman, Vinciane
    Potorac, Iulia
    Manto, Florence
    Dassy, Sarah
    Segers, Karin
    Thiry, Albert
    Bours, Vincent
    Daly, Adrian F.
    Beckers, Albert
    ENDOCRINE-RELATED CANCER, 2016, 23 (05) : 391 - 397
  • [40] Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations
    Hendrickson, Andrea E. Wahner
    Bakkum-Gamez, Jamie N.
    Couch, Fergus J.
    Ghosh, Karthik
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (11) : 3107 - 3109